prompt
stringlengths 47
204
| response
stringlengths 1
2.73k
| __index_level_0__
int64 0
1.38M
|
|---|---|---|
How should the interaction between Naproxen and Repaglinide be managed? Describe the necessary steps. | Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn. | 896,942 |
Explain the mechanism of interaction between Isoflurophate (ophthalmic) and Siponimod. | Synergy | 803,591 |
How should the interaction between Miglitol and Ritonavir be managed? Describe the necessary steps. | Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. | 256,508 |
How should the interaction between Encorafenib and Pitavastatin be managed? Describe the necessary steps. | Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy. | 572,843 |
How should the interaction between Amikacin (liposome) and Atracurium be managed? Describe the necessary steps. | The use of aminoglycosides should generally be avoided during and immediately after surgery in which neuromuscular blockers have been employed. If these agents are used concurrently, vital signs should be closely monitored and drug dosages adjusted accordingly. In addition, ventilatory support should be readily available in case of respiratory arrest. Treatment with anticholinesterases and calcium may not always be effective in reversing the neuromuscular blockade caused by these agents. | 678,843 |
What is the severity level of interaction between Fluocinonide (topical) and Acarbose? | Minor | 906,606 |
Explain the mechanism of interaction between Ribociclib and Terfenadine. | SynergyMetabolism | 1,300,571 |
What is the interaction between Darifenacin and Pyridostigmine? | Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may antagonize the effects of cholinergic skeletal muscle stimulants (e.g., ambenonium, edrophonium, guanidine, neostigmine, pyridostigmine). Although this interaction may be desirable in some situations, such as when atropine is used to treat excessive muscarinic side effects and cholinergic crisis induced by anticholinesterase overdose, unintentional or indiscriminate use of anticholinergic agents in the treatment of myasthenia gravis may exacerbate symptoms. | 648,531 |
Explain the mechanism of interaction between Chromium picolinate and Miglitol. | Synergy | 68,148 |
How should the interaction between Indinavir and Paclitaxel (protein-bound) be managed? Describe the necessary steps. | Caution is advised if paclitaxel is required in patients receiving protease inhibitors and/or delavirdine. A lower initial dosage of paclitaxel may be appropriate. Patients should be closely monitored for the development of dose-related paclitaxel toxicity such as myelosuppression, stomatitis, arthralgia, myalgia, visual disturbances and peripheral neuropathy, and the paclitaxel dosage further adjusted as necessary. Use of repaglinide with the fixed combination of atazanavir-cobicistat is not recommended. | 698,361 |
Explain the mechanism of interaction between Dexlansoprazole and Gentamicin. | Synergy | 1,253,617 |
What is the severity level of interaction between Dexmedetomidine and Meperidine? | Moderate | 1,288,205 |
Explain the mechanism of interaction between Procyclidine and Desipramine. | Synergy | 1,288,507 |
What is the interaction between Chloramphenicol and Adalimumab? | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years. | 1,319,512 |
Explain the mechanism of interaction between Abemaciclib and Posaconazole. | Metabolism | 665,987 |
Explain the mechanism of interaction between Methsuximide and Ethanol. | Synergy | 349,457 |
How should the interaction between Denosumab and Mogamulizumab be managed? Describe the necessary steps. | Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment. | 473,254 |
Explain the mechanism of interaction between Idelalisib and Fludarabine. | Synergy | 1,305,416 |
Explain the mechanism of interaction between Methadone and Histrelin. | Synergy | 489,492 |
Explain the mechanism of interaction between Fluconazole and Losartan. | Metabolism | 565,894 |
Explain the mechanism of interaction between Droperidol and Ribociclib. | Synergy | 528,178 |
What is the severity level of interaction between Atracurium and Estazolam? | Moderate | 331,236 |
Explain the mechanism of interaction between Phentolamine and Fentanyl. | Synergy | 273,538 |
Explain the mechanism of interaction between Rifabutin and Doravirine. | Metabolism | 555,839 |
How should the interaction between Oxtriphylline and Doxycycline be managed? Describe the necessary steps. | If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. Patients should be advised to notify their physician if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats. It may be necessary to reduce theophylline dosage. | 1,377,523 |
How should the interaction between Abarelix and Lumefantrine be managed? Describe the necessary steps. | Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided. Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days). Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. | 319,030 |
What is the interaction between Metformin and Rucaparib? | Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of Multidrug and Toxin Extrusion (MATE) 1, MATE 2-K, organic cation transporter (OCT) 1, and/or OCT 2. The proposed mechanism, based on in vitro data, is decreased clearance due to rucaparib-mediated inhibition of these transport proteins. Rucaparib appears to be a potent inhibitor of MATE 1 and MATE2-K, a moderate inhibitor of OCT1, and a weak inhibitor of OCT2. | 591,723 |
What is the severity level of interaction between Glasdegib and Bicalutamide? | Moderate | 953,277 |
Explain the mechanism of interaction between Deferasirox and Lepirudin. | Synergy | 84,654 |
Explain the mechanism of interaction between Solifenacin and Atropine. | Synergy | 1,178,557 |
What is the severity level of interaction between Amitriptyline and Physostigmine (ophthalmic)? | Moderate | 65,725 |
Explain the mechanism of interaction between Ziconotide and Cyproheptadine. | Synergy | 648,143 |
How should the interaction between Orphenadrine and Topiramate be managed? Describe the necessary steps. | Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. Patients, particularly pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended. Patients (or their guardians or caregivers) should contact their physician immediately if they are not sweating as usual, with or without a fever. Ambulatory patients treated with topiramate and agents with anticholinergic activity should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. | 527,035 |
Explain the mechanism of interaction between Lurbinectedin and Trichophyton mentagrophytes. | Others | 654,811 |
What is the interaction between Disopyramide and Fedratinib? | Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes. | 1,198,079 |
Explain the mechanism of interaction between Metyrosine and Dapagliflozin. | Synergy | 156,730 |
What is the interaction between Lithium carbonate and Moexipril? | Coadministration with angiotensin converting enzyme (ACE) inhibitors may increase serum lithium concentrations and the risk for lithium toxicity. Several mechanisms may be involved, one of which is reduced renal lithium clearance due to natriuresis secondary to the inhibition of aldosterone and angiotensin II by ACE inhibitors. The combination may also cause renal dysfunction secondary to volume depletion during chronic therapy, which can further impair lithium clearance. The interaction was suspected in cases of lithium toxicity that occurred up to several weeks after the initiation of ACE inhibitor therapy. | 917,040 |
Explain the mechanism of interaction between Cyclophosphamide and Diltiazem. | Metabolism | 486,232 |
Explain the mechanism of interaction between Arformoterol and Vilanterol. | Synergy | 1,307,371 |
What is the interaction between Phenobarbital and Prilocaine (topiclal)? | Prilocaine can cause dose-related methemoglobin formation via its ortho-toluidine metabolite. Coadministration with other oxidizing agents that can also induce methemoglobinemia including other local anesthetics (e.g., benzocaine, lidocaine),antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. | 989,436 |
What is the interaction between Triclabendazole and Donepezil? | Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval. | 184,779 |
What is the severity level of interaction between Oxytocin and Sunitinib? | Moderate | 1,262,752 |
How should the interaction between Promazine and Rufinamide be managed? Describe the necessary steps. | During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination. | 1,284,372 |
How should the interaction between Ipilimumab and Interferon beta-1b be managed? Describe the necessary steps. | The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. | 103,355 |
How should the interaction between Isavuconazonium and Amlodipine be managed? Describe the necessary steps. | Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis. | 791,743 |
What is the severity level of interaction between Phendimetrazine and Linagliptin? | Moderate | 1,247,617 |
What is the interaction between Dinutuximab and Trastuzumab emtansine? | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years. | 327,069 |
How should the interaction between Terbutaline and Methazolamide be managed? Describe the necessary steps. | Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat. | 1,370,455 |
How should the interaction between Diphenhydramine and Temazepam be managed? Describe the necessary steps. | During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination. | 787,201 |
How should the interaction between Stiripentol and Voriconazole be managed? Describe the necessary steps. | Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behaviour, neutropenia, and thrombocytopenia. Dosage adjustments for stiripentol or alternative treatments may be required if an interaction is suspected. | 1,113,396 |
What is the severity level of interaction between Methdilazine and Insulin detemir? | Moderate | 329,365 |
What is the severity level of interaction between Benzthiazide and Minocycline? | Minor | 41,090 |
Explain the mechanism of interaction between Mephenytoin and Alefacept. | Metabolism | 278,167 |
What is the severity level of interaction between Demeclocycline and Remdesivir? | Moderate | 1,239,911 |
What is the severity level of interaction between Granisetron and Dextromethorphan? | Major | 175,203 |
What is the interaction between Chlorthalidone and Codeine? | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis. | 912,756 |
Explain the mechanism of interaction between Isoniazid and Triamcinolone (ophthalmic). | Excretion | 1,136,074 |
What is the interaction between Zolmitriptan and Propafenone? | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of zolmitriptan, which is a substrate of the isoenzyme. | 999,890 |
What is the interaction between Itraconazole and Tucatinib? | Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates. The mechanism involves tucatinib-mediated inhibition of CYP450 3A isoenzymes. | 137,337 |
How should the interaction between Ivacaftor and Ubrogepant be managed? Describe the necessary steps. | The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors. If needed, a second ubrogepant dose should be avoided within 24 hours of the initial dose when used with moderate CYP450 3A4 inhibitors. | 1,103,462 |
Explain the mechanism of interaction between Colchicine and Larotrectinib. | Metabolism | 732,180 |
How should the interaction between Naloxegol and Felbamate be managed? Describe the necessary steps. | The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of naloxegol should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected. | 110,268 |
What is the severity level of interaction between Bisoprolol and Trimipramine? | Moderate | 259,178 |
What is the severity level of interaction between Rubella virus vaccine and Tositumomab (I-131)? | Major | 131,932 |
What is the severity level of interaction between Avanafil and Nevirapine? | Moderate | 671,155 |
What is the severity level of interaction between Kanamycin and Phenyl salicylate? | Moderate | 121,958 |